Ask AI
ASCENT 04 KEYNOTE D19
ASCENT-04//KEYNOTE-D19: Phase III Trial of First-line Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC

Released: June 03, 2025

Expiration: December 02, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 03, 2025

Expiration: December 02, 2025